Latest News about Briefs
Recent news which mentions Briefs
Monopoly Maker Hasbro Inventory Falls 39% In Q3, CFO Vows To Finish 2024 With Improved Profitability
October 24, 2024
From Benzinga
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
October 24, 2024
From Benzinga
Asia Mixed, Europe Gains, Crude Oil Jumps 2% On Geopolitical Concerns, Gold Advances - Global Markets Today While US Slept
October 24, 2024
From Benzinga
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
October 23, 2024
From Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
October 23, 2024
From Benzinga
Uber Analyst Bets New Verticals, Partnerships Will Drive Q3 Gains
October 23, 2024
From Benzinga
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
October 23, 2024
From Benzinga
From Benzinga
Philip Morris' Q3 Driven By Smoke-Free Products Amid Rising Market Share In Key Regions: Analyst Forecasts Growth Across IQOS And ZYN Brands
October 23, 2024
From Benzinga
Verizon's 5G Expansion And Fiber Goals Boost Long-Term Outlook, Analysts Cautiously Optimistic
October 23, 2024
From Benzinga
Eli Lilly Alzheimer's Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective
October 23, 2024
Tickers
LLY
From Benzinga
PayPal Expands Partnership With Global Payments, Fastlane Checkout To Boost E-Commerce
October 23, 2024
From Benzinga
Norfolk Southern's Q3 Beat Fuels Analyst Optimism Despite Q4 Challenges—Long-Term Growth Potential In Focus
October 23, 2024
From Benzinga
Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway
October 23, 2024
From Benzinga
Block To See Improved Profitability Amid Expense Discipline In Q3: Analyst Forecasts Stable Payment Volume Growth
October 23, 2024
From Benzinga
AdTech Stock Magnite Gains as Disney Renews Key Deal, Expands ESPN and Podcast Offerings
October 23, 2024
From Benzinga
3M's Earnings Impress, Yet Analysts See Long Road Ahead With Cyclical Recovery And PFAS Risks
October 23, 2024
From Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
October 23, 2024
From Benzinga
Shell Fuels The Future: New Deal with Ferrari And Power Plant Acquisition On The Horizon
October 23, 2024
From Benzinga
From Benzinga
General Motors Growth Potential In Focus Amid EV Transition: Analyst Highlights Robust Liquidity, More Buybacks
October 23, 2024
From Benzinga
From Benzinga
What's Going On With Nvidia Stock On Wednesday?
October 23, 2024
From Benzinga
Avery Dennison's Mixed Q3: Earnings Beat, Revenue Falls Short, Tightens Annual Outlook & More
October 23, 2024
From Benzinga
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
October 23, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
